Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a therapeutic approach used to achieve curative treatment in intra-abdominal malignancy with peritoneal carcinomatosis (PC). However, it is a complicated procedure with high post-operative complication rates. Thus, we analyzed our preliminary data to establish whether multidisciplinary teamwork (MDT) implementation is beneficial for CRS-HIPEC outcomes.
Method: A series of 132 consecutive patients with synchronous or recurrent PC secondary to gastrointestinal or gynecologic cancer who received CRS-HIPEC operation between May 2015 and September 2017 were included. Ninety-nine patients were categorized into the MDT group, with the 33 other patients into the non-MDT group.
Results: The mean PCI score was 16.3 ± 8.8. Patients in the MDT group more often presented a higher PCI score ( value = 0.038). Regarding CRS completeness (CCR 0-1), it was distributed 81.8% and 57.6% in the MDT and the non-MDT group, respectively ( value = 0.005). Although post-operative complications were common ( = 62, 47.0%), post-operative complication rates did not differ between the two groups. The cumulative OS survival rate at the first year was 75.5%. Older age ( = 0.030, HR = 4.58, 95% CI = 1.16-18.10), ECOG 2 ( = 0.030, HR = 6.41, 95% CI = 1.20-34.14), and incomplete cytoreduction ( = 0.048, HR = 2.79, 95% CI = 1.04-8.27) were independent prognostic factors for survival.
Conclusions: Our experience suggests that the CRS-HIPEC performed under MDT cooperation may result in higher complete cytoreduction rates without increasing post-operative complications and hospital mortalities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705741 | PMC |
http://dx.doi.org/10.3390/jpm11121313 | DOI Listing |
Crit Care Res Pract
December 2024
Gastro-Intestinal and HPB Services, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has become standard treatment for peritoneal cancers and metastases, significantly enhancing survival rates. This study evaluated the relationship between tumor burden, hemodynamic management, and postoperative outcomes after CRS-HIPEC. This study included 203 patients undergoing CRS-HIPEC.
View Article and Find Full Text PDFClin Case Rep
January 2025
Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences Okayama University Okayama Japan.
Blunt abdominal trauma causing intraperitoneal injury and/or bleeding can be life-threatening, requiring immediate intervention. Diagnosing these cases can be challenging, especially when pre-existing conditions are involved. Low-grade appendiceal mucinous neoplasm (LAMN) is a rare tumor of the appendix that can lead to pseudomyxoma peritonei.
View Article and Find Full Text PDFEur Urol Open Sci
January 2025
Department of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Background And Objective: Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study.
Methods: Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC.
Int Cancer Conf J
January 2025
Department of Pathology, Comprehensive Cancer Center, Institut de Cancérologie de L'Ouest, Angers, France.
Foreign body granuloma (FBG) is an inflammatory reaction to an exogenous agent. This entity is well known on the cutaneous organ but very rarely described in the abdominal cavity. We report three clinical cases of intraperitoneal FBG following major debulking of pseudomyxoma and intraperitoneal hyperthermia chemotherapy.
View Article and Find Full Text PDFInt Cancer Conf J
January 2025
Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507 Japan.
The combination therapy of lenvatinib plus pembrolizumab (LP) is increasingly recognized as an important second-line regimen for advanced or recurrent endometrial cancer (EC). However, the safety and efficacy of conversion surgery with low anterior rectal resection for unresectable EC following LP therapy is unknown. A 37-year-old woman was referred with unresectable EC with pleural fluid, peritoneal dissemination, and ascites.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!